All AbMole products are for research use only, cannot be used for human consumption.
KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I and Aurora kinase that induces cytotoxicity in Molm14 cells (which harbor an FLT3/ITD mutation). In addition, KW-2449 potently inhibited ABL-T315I, which is associated with IM resistance, with an IC50 value of 4 nM. KW-2449 showed the potent growth inhibitory effects on leukemia cells with FLT3 mutations by inhibition of the FLT3 kinase, resulting in the down-regulation of phosphorylated-FLT3/STAT5, G(1) arrest, and apoptosis. Oral administration of KW-2449 showed dose-dependent and significant tumor growth inhibition in FLT3-mutated xenograft model with minimum bone marrow suppression. In FLT3 wild-type human leukemia, it induced the reduction of phosphorylated histone H3, G(2)/M arrest, and apoptosis. In imatinib-resistant leukemia, KW-2449 contributed to release of the resistance by the simultaneous down-regulation of BCR/ABL and Aurora kinases. KW-2449 has significant activity and warrants clinical study in leukemia patients with FLT3 mutations as well as imatinib-resistant mutations.
 |
Source | Clin Cancer Res (2011). Figure 1. KW-2449 |
| Method | Assessment of apoptosis | |
| Cell Lines | CML cells | |
| Concentrations | 0.2–0.6 μM | |
| Incubation Time | 72 h | |
| Results | KW2449 synergistically enhances the lethality of vorinostat/SNDX275 in CML cells |
| Cell Experiment | |
|---|---|
| Cell lines | K562 and LAMA cells line |
| Preparation method | Assessment of apoptosis The extent of apoptosis was evaluated by either annexin V-fluorescein isothiocyanate staining (BD Pharmigen) or 7-aminoactinomycin D (Sigma–Aldrich) by flow cytometry as described previously (19, 20). |
| Concentrations | 0.4 μmol/L |
| Incubation time | 72 or 48 h |
| Animal Experiment | |
|---|---|
| Animal models | CBySmn.CB17-Prkdsscid/J (BALB/C) mice (The Jackson Laboratory) BV173/E255K/Luc cl4 cells tumour model |
| Formulation | dissolved in 0.5% methylcellulose 400 solution (Wako) |
| Dosages | 32 mg/kg/d, 5 d/wk |
| Administration | orally (p.o.) |
| Molecular Weight | 332.4 |
| Formula | C20H20N4O |
| CAS Number | 1000669-72-6 |
| Solubility (25°C) | DMSO 57 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Sato T, et al. Blood. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
| Related FLT3 Products |
|---|
| 4SC-203
4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. |
| AKN-028
AKN-028, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. |
| FLT3-IN-3
FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively. |
| MAX-40279
MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. |
| FLT3-IN-10
FLT3-IN-10 is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
